1556008
USP
醋酸泼尼松龙
United States Pharmacopeia (USP) Reference Standard
别名:
醋酸泼尼松龙, 1,4-孕甾二烯-11β,17α,21-三醇-3,20-二酮 21-醋酸酯, 11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮 21-醋酸酯, 21-乙酰氧基-1,4-孕甾二烯-11β,17α-二醇-3,20-二酮
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C23H30O6
CAS号:
分子量:
402.48
Beilstein:
3111798
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
API 家族
prednisolone
製造商／商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
2-8°C
SMILES 字串
[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)COC(C)=O
InChI
1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1
InChI 密鑰
LRJOMUJRLNCICJ-JZYPGELDSA-N
基因資訊
human ... NR3C1(2908)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Danger
危險聲明
危險分類
Repr. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
Wool Suh et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 29(7), 646-651 (2013-04-30)
To evaluate the effect of bevacizumab in trabeculectomies with 5-fluorouracil (5-FU). Thirty-six patients with uncontrolled glaucoma were included. Twelve patients underwent trabeculectomies with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5-FU (5.0 mg/0.5 mL). The control group underwent
Salima I Hassanaly et al.
American journal of ophthalmology, 158(2), 270-276 (2014-05-23)
To describe outcomes after Boston Type 1 Keratoprosthesis (KPro) surgery in aniridic eyes. Retrospective, interventional case series. University-based tertiary care institution. Twenty-six aniridic eyes of 19 patients who underwent KPro implantation by a single experienced surgeon (M.H.-D.) between October 27
Marcus Ang et al.
American journal of ophthalmology, 157(6), 1163-1169 (2014-03-04)
To compare 3-year endothelial cell loss and graft survival following Descemet stripping automated endothelial keratoplasty (DSAEK) using the EndoGlide (AngioTech, Reading, Pennsylvania, USA/Network Medical Products, North Yorkshire, UK) donor insertion device compared to donor insertion using the Sheets glide technique.
Antigoni Koukkoulli et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 253(1), 99-106 (2014-10-12)
To report on long-term outcomes of mitomycin C (MMC)-augmented needle revision of failing deep sclerectomy (DS) blebs. Retrospective database search of all needle revisions with MMC for DS blebs between 2002 and 2008 was conducted. Sixty-six eyes of 66 patients
Rohit Shetty et al.
Indian journal of ophthalmology, 62(9), 923-926 (2014-11-06)
To study the safety and efficacy of sutureless femtosecond anterior lamellar keratoplasty (FALK) in patients with corneal stromal opacities. Eleven eyes of 11 consecutive patients with corneal stromal opacities involving < 250 μ due to various pathologies were included in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门